Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX – Get Free Report) saw a large increase in short interest in October. As of October 31st, there was short interest totalling 76,700 shares, an increase of 89.4% from the October 15th total of 40,500 shares. Based on an average daily volume of 32,400 shares, the short-interest ratio is currently 2.4 days. Approximately 1.0% of the company’s shares are short sold.
Wall Street Analyst Weigh In
Separately, StockNews.com assumed coverage on Cumberland Pharmaceuticals in a report on Sunday. They set a “hold” rating for the company.
Check Out Our Latest Report on Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Stock Down 1.7 %
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
Recommended Stories
- Five stocks we like better than Cumberland Pharmaceuticals
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Rocket Lab is the Right Stock for the Right Time
- What is the Dow Jones Industrial Average (DJIA)?
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.